Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hu-Qian Wan is a classical Traditional Chinese Medicine (TCM) polyherbal formulation originally documented by the physician Zhu Danxi in the 14th-century text *Danxi Xinfa*. It is traditionally indicated for the treatment of Atrophy Syndrome (Wei Zheng), characterized by weakness, soreness, and wasting of the lower limbs, typically attributed to Kidney and Liver Yin deficiency with associated 'empty heat.' The standard formulation comprises several key botanicals, including *Phellodendron chinense* (Huang Bai), *Anemarrhena asphodeloides* (Zhi Mu), *Rehmannia glutinosa* (Shu Di Huang), and *Chinemys reevesii* plastron (Gui Ban). In modern pharmacological research, Hu-Qian Wan has been investigated for its neuroprotective properties in neurodegenerative conditions like Amyotrophic Lateral Sclerosis (ALS) and its ability to inhibit bone resorption in osteoporosis. It appears to act by suppressing pro-inflammatory cytokines, reducing oxidative stress, and modulating the RANKL/OPG signaling pathway to inhibit osteoclastogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hu-Qian Wan.